This article is available to subscribers. Subscribe now. Already have an account? Sign in

EditorialFree Preview

T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma

List of authors.
  • Sham Mailankody, M.B., B.S.,
  • and Ola Landgren, M.D., Ph.D.

B-cell maturation antigen (BCMA) was identified as a prognostic marker in multiple myeloma more than two decades ago. Starting in 2014, the first use of BCMA as a treatment target was evaluated in patients with multiple myeloma who received chimeric antigen receptor (CAR) T cells.1,2 Today, a range of myeloma treatments target BCMA, including CAR T cells, along with antibody drug conjugates and bispecific antibodies; some agents are in development, and some have been approved by the Food and Drug Administration (FDA).3 The rapid translation from preclinical studies to several FDA-approved treatments is a new chapter in the remarkable success . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org.

Author Affiliations

From the Myeloma and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (S.M.); and the Division of Myeloma, Sylvester Comprehensive Cancer Center, University of Miami, Miami (O.L.).